Overview

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

Status:
Active, not recruiting

Trial end date:
2031-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source [example, access program or government program]), or local standard of care, as appropriate.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen R&D Ireland
Janssen Sciences Ireland UC

Treatments:

Etravirine